摘要
目的:探讨小鼠肾包膜下移植肿瘤药敏测定(SRCA)在复发耐药NHL治疗中的作用.方法:对25例CHOP方案化疗后出现复发耐药的NHL病人进行了SRCA药敏测定,并依据SRCA结果进行化疗.结果:NHL肿瘤细胞在小鼠肾包膜下能够快速生长,移植成功率100%;复发耐药NHL对CTX、VCR、ADM表现为耐药,而对VP_(16)、MTX、DDP敏感性较高,其中对VP_(16)的敏感性显著高于CTX和VCR(P<0.05);依据药敏结果化疗,25例病人6例CR、13例PR,总有效率76%;其中21例接受由VP_(16)、MTX、DDP和强的松组成的方案治疗,6例CR,11例PR,有效率达81%.结论:NHL适宜用SRCA法进行药敏测定;复发耐药NHL的治疗可以VP_(16)、MTX和DDP为基础;化疗前进行SRCA药敏测定,能够减少用药盲目性,提高有效率.
Purpose:To investigate the clinical value of mouse subrenal capsule assay (SRCA) in refractory non-Hodgkin's lymphoma(NHL) . Methods: 25 NHL patients who were relapsed or drug-resisted after CHOP regimen treatment were underwent SRCA, and their following chemotherapy was based on the SRCA outcome. Results:The NHL cell grew rapidly un-der mice renal capsule within 5 days and the evaluability rate was 100% , the anticancer activity of 6 common used drug from high to low was in the order of VP_(16)?MTX?DDP?ADM? VCR and CTX, VP_(16) had a significantly higher anticancer activity than CTX and VCR (Ridit test,P<0. 05) ; In 25 patients treated according to SRCA outcome, 6 cases achieved CR, 13 PR, the overall ob-jective response rate was 76% ; In 21 patients treated with regimen comtaining VP_(16) MTX?DDP and Pred as indicated by SRCA, 6 achieved CR and 11 PR, the objective response rate was 81%. Conclusions: The refractory NHL is suitable to SRCA for drug sensitirity assay and its treatment regimen should base on VP_(16)?MTX and DDP; It could avoid blindness in the treatment to make SRCA before chemotherapy.
出处
《临床肿瘤学杂志》
CAS
1998年第1期1-3,共3页
Chinese Clinical Oncology
